Skip to main content
Article thumbnail
Location of Repository

Conference scene : Golden Helix Pharmacogenomics Days : educational activities on pharmacogenomics and personalized medicine

By Alessio Squassina, Giovanni Severino, Godfrey Grech, Anthony G. Fenech, Joseph J. Borg and George P. Patrinos


The Golden Helix Pharmacogenomics Days are high-profile international educational scientific meetings discussing pharmacogenomics and personalized medicine. Here, we provide an overview of the scientific lectures and the topics discussed during the 4th Golden Helix Pharmacogenomics Day, held in Cagliari, Italy, on 7 October 2011, and the 5th Golden Helix Pharmacogenomics Day, that was held in Msida, Malta, on 3 December 2011. The scientific programs of both events included scientific and company lectures on pharmacogenomics, bioinformatics and personalized medicine by local and international speakers from Europe and the USA.peer-reviewe

Topics: Personalized medicine, Pharmacogenomics, Pharmacogenetics -- Social aspects -- Malta
Publisher: Future Medicine Ltd
Year: 2012
DOI identifier: 10.2217/PGS.12.22
OAI identifier:
Provided by: OAR@UM

Suggested articles


  1. Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. doi
  2. (2011). Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. doi
  3. (2011). Giese A et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. doi
  4. (2012). Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. doi
  5. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. doi
  6. (2008). Kolbus A et al. Igbp1 is part of a positive feedback loop in SCFdependent, selective mRNA translation initiation inhibiting erythroid differentiation. doi
  7. (2011). Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol. Drug Interact. doi
  8. (2011). Targeting the Akt/mTOR pathway in Brca1deficient cancers. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.